nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Air travel in the time of COVID-19
|
The Lancet Infectious Diseases, |
|
|
20 |
9 |
p. 993 |
artikel |
2 |
Alison Galvani—a modeller whose career has flourished early
|
Kirby, Tony |
|
|
20 |
9 |
p. 1021 |
artikel |
3 |
A provocative intellectual history of HIV
|
Hodes, Rebecca |
|
|
20 |
9 |
p. 1024 |
artikel |
4 |
Assessment of patients who tested positive for COVID-19 after recovery
|
Mei, Qi |
|
|
20 |
9 |
p. 1004-1005 |
artikel |
5 |
Asymptomatic SARS-CoV-2 infection
|
Ooi, Eng Eong |
|
|
20 |
9 |
p. 996-998 |
artikel |
6 |
Baricitinib for COVID-19: a suitable treatment?
|
Favalli, Ennio G |
|
|
20 |
9 |
p. 1012-1013 |
artikel |
7 |
Baricitinib for COVID-19: a suitable treatment? – Authors' reply
|
Richardson, Peter J |
|
|
20 |
9 |
p. 1013-1014 |
artikel |
8 |
Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective analysis
|
Tabata, Sakiko |
|
|
20 |
9 |
p. 1043-1050 |
artikel |
9 |
Communicating with children about COVID-19
|
Mitchell, Fiona |
|
|
20 |
9 |
p. 1023 |
artikel |
10 |
Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics
|
Petersen, Eskild |
|
|
20 |
9 |
p. e238-e244 |
artikel |
11 |
Contact lens-related fungal keratitis
|
Cheung, Nam N |
|
|
20 |
9 |
p. 1100 |
artikel |
12 |
Correction to Lancet Infect Dis 2020; 20: 892–93
|
|
|
|
20 |
9 |
p. e215 |
artikel |
13 |
Correction to Lancet Infect Dis 2020; 20: 533–34
|
|
|
|
20 |
9 |
p. e215 |
artikel |
14 |
Correction to Lancet Infect Dis 2020; published online July 2. https://doi.org/10.1016/S1473-3099(20)30527-2
|
|
|
|
20 |
9 |
p. e215 |
artikel |
15 |
Correction to Lancet Infect Dis 2020; published online July 17. https://doi.org/10.1016/S1473-3099(20)30274-7
|
|
|
|
20 |
9 |
p. e215 |
artikel |
16 |
Correction to Lancet Infect Dis 2020; published online June 15. https://doi.org/10.1016/S1473-3099(20)30466-7
|
|
|
|
20 |
9 |
p. e215 |
artikel |
17 |
COVID-19: when should quarantine be enforced?
|
Bauch, Chris T |
|
|
20 |
9 |
p. 994-995 |
artikel |
18 |
CT screening for early diagnosis of SARS-CoV-2 infection
|
Huang, Yongshun |
|
|
20 |
9 |
p. 1010-1011 |
artikel |
19 |
CT screening for early diagnosis of SARS-CoV-2 infection – Authors' reply
|
Shi, Heshui |
|
|
20 |
9 |
p. 1011 |
artikel |
20 |
Elimination of COVID-19: what would it look like and is it possible?
|
Heywood, Anita E |
|
|
20 |
9 |
p. 1005-1007 |
artikel |
21 |
Flossie Wong-Staal
|
Kenyon, Georgina |
|
|
20 |
9 |
p. 1022 |
artikel |
22 |
Immunogenicity of three sequential schedules with Sabin inactivated poliovirus vaccine and bivalent oral poliovirus vaccine in Zhejiang, China: an open-label, randomised, controlled trial
|
He, Hanqing |
|
|
20 |
9 |
p. 1071-1079 |
artikel |
23 |
Inclusion of pregnant women in COVID-19 vaccine development
|
Heath, Paul T |
|
|
20 |
9 |
p. 1007-1008 |
artikel |
24 |
Individual quarantine versus active monitoring of contacts for the mitigation of COVID-19: a modelling study
|
Peak, Corey M |
|
|
20 |
9 |
p. 1025-1033 |
artikel |
25 |
Infectious disease surveillance update
|
Zwizwai, Ruth |
|
|
20 |
9 |
p. 1019 |
artikel |
26 |
Invisible spread of SARS-CoV-2
|
Xiong, Nian |
|
|
20 |
9 |
p. 1011-1012 |
artikel |
27 |
Invisible spread of SARS-CoV-2 – Authors' reply
|
Kucharski, Adam J |
|
|
20 |
9 |
p. 1012 |
artikel |
28 |
It's worse than we thought: the US market for novel Gram-negative antibiotics
|
Clancy, Cornelius J |
|
|
20 |
9 |
p. 1009-1010 |
artikel |
29 |
Looking for the optimal treatment of uncomplicated urinary tract infections
|
Verheij, Theo J M |
|
|
20 |
9 |
p. 1001-1002 |
artikel |
30 |
Mycobacterium bovis infection mimicking pancreatic cancer
|
Yates, Joseph R |
|
|
20 |
9 |
p. 1099 |
artikel |
31 |
New fund stimulates the ailing antibiotic pipeline
|
McCall, Becky |
|
|
20 |
9 |
p. 1017 |
artikel |
32 |
Racism and medical education
|
Khan, Shujhat |
|
|
20 |
9 |
p. 1009 |
artikel |
33 |
Reappraisal of the treatment duration of antibiotic regimens for acute uncomplicated cystitis in adult women: a systematic review and network meta-analysis of 61 randomised clinical trials
|
Kim, Do Kyung |
|
|
20 |
9 |
p. 1080-1088 |
artikel |
34 |
Recent successes in therapeutics for Ebola virus disease: no time for complacency
|
Iversen, Patrick L |
|
|
20 |
9 |
p. e231-e237 |
artikel |
35 |
Research brief
|
Devi, Sharmila |
|
|
20 |
9 |
p. 1020 |
artikel |
36 |
Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study
|
de Lusignan, Simon |
|
|
20 |
9 |
p. 1034-1042 |
artikel |
37 |
Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial
|
Stephenson, Kathryn E |
|
|
20 |
9 |
p. 1061-1070 |
artikel |
38 |
SARS-CoV-2 shedding and seroconversion among passengers quarantined after disembarking a cruise ship: a case series
|
Hung, Ivan Fan-Ngai |
|
|
20 |
9 |
p. 1051-1060 |
artikel |
39 |
Sequential inactivated and oral poliovirus vaccine schedules: a balancing act
|
Zaman, Khalequ |
|
|
20 |
9 |
p. 999-1000 |
artikel |
40 |
Serology testing in the COVID-19 pandemic response
|
Peeling, Rosanna W |
|
|
20 |
9 |
p. e245-e249 |
artikel |
41 |
Smell and taste dysfunction in patients with COVID-19
|
Xydakis, Michael S |
|
|
20 |
9 |
p. 1015-1016 |
artikel |
42 |
The origin of SARS-CoV-2
|
Burki, Talha |
|
|
20 |
9 |
p. 1018-1019 |
artikel |
43 |
The uncertainty of tuberculosis diagnosis
|
Datta, Sumona |
|
|
20 |
9 |
p. 1002-1004 |
artikel |
44 |
The value of antimicrobial peptides in the age of resistance
|
Magana, Maria |
|
|
20 |
9 |
p. e216-e230 |
artikel |
45 |
Utility of broad-spectrum antibiotics for diagnosing pulmonary tuberculosis in adults: a systematic review and meta-analysis
|
Divala, Titus H |
|
|
20 |
9 |
p. 1089-1098 |
artikel |
46 |
Utility of hyposmia and hypogeusia for the diagnosis of COVID-19
|
Bénézit, François |
|
|
20 |
9 |
p. 1014-1015 |
artikel |
47 |
Vaccine development during global epidemics: the Zika experience
|
Castanha, Priscila M S |
|
|
20 |
9 |
p. 998-999 |
artikel |
48 |
Who is most likely to be infected with SARS-CoV-2?
|
Jordan, Rachel E |
|
|
20 |
9 |
p. 995-996 |
artikel |